|Dr. Marc Rubin||Exec. Chairman||295k||N/A||1955|
|Mr. Sunil Bhonsle||Pres, CEO, Principal Financial Officer & Director||395k||N/A||1950|
|Dr. Katherine L. Beebe-DeVarney Ph.D.||Exec. VP & Chief Scientific Officer||N/A||N/A||1961|
|Mr. Dane D. Hallberg||Exec. VP & Chief Commercial Officer||N/A||N/A||1969|
|Jennifer Kiernan||Exec. Assistant to CEO & Investor Communications Coordinator||N/A||N/A||N/A|
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction in patients. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
Titan Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.